Circulating transforming growth factor-β1, lipoprotein(a) and cellular adhesion molecules in angiographically assessed coronary artery disease

被引:12
|
作者
Bogavac-Stanojevic, N
Djurovic, S
Jelic-Ivanovic, Z
Spasojevic-Kalimanovska, V
Kalimanovska-Ostric, D
机构
[1] Univ Belgrade, Sch Pharm, Inst Med Biochem, Fac Pharm, YU-11000 Belgrade, Serbia
[2] Ullevaal Univ Hosp, Dept Med Genet, Oslo, Norway
[3] Clin Ctr Serbia, Inst Cardiovasc Dis, Belgrade, Serbia
关键词
adhesion molecules; atherosclerosis; lipoprotein(a): Lp(a); transforming growth factor-beta(1): TGF-beta(1);
D O I
10.1515/CCLM.2003.135
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Transforming growth factor-beta(1) (TGF-beta(1)) is involved in different physiological and pathological processes, including atherogenesis. High plasma lipoprotein(a) (Lp(a)) concentration is an established independent risk factor that may interfere with the plasmin-mediated TGF-beta(1) activation. Both Lp(a) and TGF-beta(1) are thought to influence the expression of cellular adhesion molecules (CAMs), also involved in the process of atherogenesis. Whereas many studies confirmed the association between high plasma Lp(a) levels and coronary artery disease (CAD), conflicting results were obtained in different studies in which the changes of TGF-beta(1) and CAM concentrations in,CAD patients were investigated. The aim of this case-control study was to explore the association of circulating TGF-beta(1), Lp(a) and CAMs (intracellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and E-selectin) levels with the occurrence and severity of angiographically assessed coronary artery disease. Plasma TGF-beta(1), Lp(a), ICAM-1, VCAM-1 and E-selectin concentrations were measured in 100 patients with angiographically assessed CAD and 100 healthy blood donors matched according to age and gender. Lp(a) and TGF-beta(1) were significantly higher in patients than in healthy controls (p<0.001 and p<0.01, respectively), but no significant correlation between the TGF-beta(1) and Lp(a) values was found. The CAM concentrations obtained in CAD patients did not differ significantly as compared with the corresponding values in the controls. None of the measured parameters were influenced by the severity of CAD.
引用
收藏
页码:893 / 898
页数:6
相关论文
共 50 条
  • [31] Increased plasma levels of cystatin C and transforming growth factor-β1 in patients with coronary artery ectasia:: can there be a potential interaction between cystatin C and transforming growth factor-β1
    Yetkin, Ertan
    Acikgoz, Nusret
    Sivri, Nasir
    Tekin, Gulacan O.
    Yagmur, Julide
    Aksoy, Yuksel
    Turhan, Hasan
    CORONARY ARTERY DISEASE, 2007, 18 (03) : 211 - 214
  • [32] Dynamic Monitoring of Cellular Remodeling Induced by the Transforming Growth Factor-β1
    Starsichova, Andrea
    Kubala, Lukas
    Lincova, Eva
    Pernicova, Zuzana
    Kozubik, Alois
    Soucek, Karel
    BIOLOGICAL PROCEDURES ONLINE, 2009, 11 (01) : 316 - 324
  • [33] Dynamic Monitoring of Cellular Remodeling Induced by the Transforming Growth Factor-β1
    Andrea Staršíchová
    Lukáš Kubala
    Eva Lincová
    Zuzana Pernicová
    Alois Kozubík
    Karel Souček
    Biological Procedures Online, 11
  • [34] Bioactive molecules in milk and their role in health and disease:: The role of transforming growth factor-β
    Donnet-Hughes, A
    Duc, N
    Serrant, P
    Vidal, K
    Schiffrin, EJ
    IMMUNOLOGY AND CELL BIOLOGY, 2000, 78 (01): : 74 - 79
  • [35] Circulating transforming growth factor-β1 -: A potential marker of disease activity during idiopathic pulmonary fibrosis
    Yong, SJ
    Adlakha, A
    Limper, AH
    CHEST, 2001, 120 (01) : 68S - 70S
  • [36] Implication of transforming growth factor-β1 in chagas disease myocardiopathy
    Araújo-Jorge, TC
    Waghabi, MC
    Hasslocher-Moreno, AM
    Xavier, SS
    Higuchi, MD
    Keramidas, M
    Bailly, S
    Feige, JJ
    JOURNAL OF INFECTIOUS DISEASES, 2002, 186 (12): : 1823 - 1828
  • [37] Activation of transforming growth factor-β1 in diabetic kidney disease
    Hellmich, B
    Schellner, M
    Schatz, H
    Pfeiffer, A
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2000, 49 (03): : 353 - 359
  • [38] Role of transforming growth factor-β1 in the pathogenesis of moyamoya disease
    Hojo, M
    Hoshimaru, M
    Miyamoto, S
    Taki, W
    Nagata, I
    Asahi, M
    Matsuura, N
    Ishizaki, R
    Kikuchi, H
    Hashimoto, N
    JOURNAL OF NEUROSURGERY, 1998, 89 (04) : 623 - 629
  • [39] Circulating transforming growth factor-β1 levels in asymptomatic carotid plaques -: Response
    Cipollone, F
    Mezzetti, A
    STROKE, 2005, 36 (03) : 525 - 526
  • [40] Adhesion formation can be reduced by the suppression of transforming growth factor-β1 activity
    Fukui, N
    Tashiro, T
    Hiraoka, H
    Oda, H
    Nakamura, K
    JOURNAL OF ORTHOPAEDIC RESEARCH, 2000, 18 (02) : 212 - 219